GlassScriptPhysician profile
Clarence T Joustra
NPI 1942202080
$1,775.53
in general payments reported to CMS, 2019-2025
21 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $156 · 2021: $277 · 2022: $276 · 2023: $245 · 2024: $206 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.49 | 2019-2023 | Xifaxan |
| Pfizer INC. | $318.61 | 2019-2025 | |
| Abbvie INC. | $272.79 | 2019-2023 | |
| Lundbeck LLC | $199.33 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $172.15 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.44 | 2021-2025 | Caplyta |
| Ardelyx, INC. | $50.00 | 2024 | Ibsrela |
| Indivior INC. | $37.94 | 2022 | |
| Sunovion Pharmaceuticals INC. | $35.73 | 2019 | |
| Verona Pharma, INC. | $28.29 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $22.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.58 | 2025 | Eliquis |
| Dexcom, INC. | $15.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.20 | 2024 | Breztri |
| Ucb, INC. | $14.57 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $14.12 | 2021 | |
| Novo Nordisk INC | $13.79 | 2021 | |
| Mylan Specialty L.P. | $12.30 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.87 | 2019 | |
| Eisai INC. | $11.65 | 2020 | |
| Allergan, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Joustra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.